Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP1A1m1 and CYP2C92 and 3 polymorphism and risk to develop ARV-associated hepatotoxicity and its severity.

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica - 1 Jun 2017

Singh HariOm, Lata Sonam, Nema Vijay, Samani Dharmesh, Ghate Manisha, Gangakhedkar Raman R

Abstract excerpt

Non-nucleoside reverse transcriptase inhibitors are metabolized in the liver by cytochrome P450 (CYP) isoenzymes. Variations in the genes encoding these enzymes may influence the activity of corresponding metabolizing enzymes. This study aimed at assessing association of CYP2C9*2 430C/T, CYP2C9*31075A/C, and CYP1A1m1 3801T/C polymorphism with risk to develop ARV Antiretroviral-associated hepatotoxicity and its...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Retroviral Agents
Share to Chemical and Drug Induced Liver Injury

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP1A1

Share to Cytochrome P-450 CYP2C9

Share to Genotyping Techniques

Share to Polymorphism, Restriction Fragment Length

Share to Risk Assessment

Share to Severity of Illness Index

Source

Identifiers

PMID: 28370504
DOI: 10.1111/apm.12683

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP1A1m1 and CYP2C9*2 and *3 polymorphism and risk to develop ARV-associated hepatotoxicity and its severity.PMID 28370504Read ↗

Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity.Semantic proximity Read ↗

The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition.Semantic proximity Read ↗

Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent.Semantic proximity Read ↗

Prevalence of ABCC3-1767G/A polymorphism among patients with antiretroviral-associated hepatotoxicity.Semantic proximity Read ↗

Analysis of MDR1 Polymorphisms Among HIV-Infected Individuals on ARV Therapy from Western IndiaSemantic proximity Read ↗

Impact of GSTM1, GSTT1 and GSTP1 gene polymorphism and risk of ARV-associated hepatotoxicity in HIV-infected individuals and its modulation.Semantic proximity Read ↗

Analysis of MDR1 Polymorphisms Among HIV-Infected Individuals on ARV Therapy from Western IndiaSemantic proximity Read ↗

Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique.Semantic proximity Read ↗

[Toxicogenetics of antiretroviral treatment (II): neurotoxicity, hepatotoxicity, lactic acidosis, kidney damage, and other adverse effects of antiretroviral drugs].Semantic proximity Read ↗

Pharmacogenetic associations with cytochrome P450 in antiretroviral therapy: what does the future hold?Semantic proximity Read ↗

ABCG2 polymorphisms and susceptibility to ARV-associated hepatotoxicity.Semantic proximity Read ↗

IL-1RN and IL-1β Polymorphism and ARV-Associated Hepatotoxicity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.